Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + fentanyl + sevoflurane (Heidelberg University, 4ca7e9)
- Development stage
- Phase 4
- Lead developer
- Universitat Heidelberg
- Modality
- Small Molecules
- Administration
- Intravenous, Inhalation
01
Overview
This anesthetic regimen is a combination of three established pharmacological agents: propofol, fentanyl, and sevoflurane. It was utilized as a research protocol by Heidelberg University in a randomized controlled trial (NCT02794896) to investigate the effects of anesthetic depth on the immune response in patients undergoing extended shoulder surgery. In this 'balanced anesthesia' approach, propofol is typically used for the induction of anesthesia, fentanyl serves as a potent opioid analgesic to manage perioperative pain, and sevoflurane is an inhaled volatile anesthetic used for the maintenance of the hypnotic state. The study specifically examined how varying depths of anesthesia, monitored via the bispectral index (BIS), influenced cellular immunity, including the proliferation of Natural Killer (NK) cells, T-cells, and the activity of monocytes and neutrophils.
- Other names
- High dose propofol, fentanyl and sevofluraneLow dose propofol, fentanyl and sevofluraneBalanced anesthesia
02
Targets
GABRR (GABA-A receptor subunit rho)Glycine receptorMOR (Mu opioid receptor)Nicotinic Acetylcholine ReceptorHTR3A (5-hydroxytryptamine receptor 3A)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on propofol + fentanyl + sevoflurane (Heidelberg University, 4ca7e9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + fentanyl + sevoflurane (Heidelberg University, 4ca7e9).